July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-induced Ocular Hypertensive Monkeys
Author Affiliations & Notes
  • Masahiro Fuwa
    Santen Pharmaceutical Co., Ltd., Ikoma, Japan
  • Carol B Toris
    Department of Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska, United States
    Department of Ophthalmology, Case Western Reserve University, Cleveland, Ohio, United States
  • Shan Fan
    Department of Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska, United States
  • Takazumi Taniguchi
    Santen Pharmaceutical Co., Ltd., Ikoma, Japan
  • Masaki Ichikawa
    Santen Pharmaceutical Co., Ltd., Ikoma, Japan
  • Noriko Odani-Kawabata
    Santen Pharmaceutical Co., Ltd., Osaka, Japan
  • Ryo Iwamura
    Ube Industries, Ltd., Ube, Japan
  • Kenji Yoneda
    Ube Industries, Ltd., Ube, Japan
  • Takeshi Matsugi
    Santen Pharmaceutical Co., Ltd., Ikoma, Japan
  • Naveed Kamal Shams
    Santen Pharmaceutical Co., Ltd., Osaka, Japan
    Santen Inc., Emeryville, California, United States
  • Jin-Zhong Zhang
    Santen Pharmaceutical Co., Ltd., Ikoma, Japan
    Santen Inc., Emeryville, California, United States
  • Footnotes
    Commercial Relationships   Masahiro Fuwa, Santen Pharmaceutical Co., Ltd. (E); Carol Toris, Case Western Reserve University (F), Santen Pharmaceutical Co., Ltd. (F), University of Nebraska Medical Center (F); Shan Fan, None; Takazumi Taniguchi, Santen Pharmaceutical Co., Ltd. (E); Masaki Ichikawa, Santen Pharmaceutical Co., Ltd. (E); Noriko Odani-Kawabata, Santen Pharmaceutical Co., Ltd. (E); Ryo Iwamura, Ube Industries, Ltd. (E); Kenji Yoneda, Ube Industries, Ltd. (E); Takeshi Matsugi, Santen Pharmaceutical Co., Ltd. (E); Naveed Shams, Santen Inc. (E); Jin-Zhong Zhang, Santen Inc. (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2717. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Masahiro Fuwa, Carol B Toris, Shan Fan, Takazumi Taniguchi, Masaki Ichikawa, Noriko Odani-Kawabata, Ryo Iwamura, Kenji Yoneda, Takeshi Matsugi, Naveed Kamal Shams, Jin-Zhong Zhang; Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-induced Ocular Hypertensive Monkeys. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2717.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the mechanism of the intraocular pressure (IOP)-lowering effect of a novel selective EP2 receptor agonist, omidenepag isopropyl (OMDI).

Methods : The effect of OMDI on IOP and aqueous humor dynamics was evaluated in cynomolgus monkeys with unilateral laser-induced ocular hypertension. In a crossover fashion, the hypertensive eye of each monkey was dosed once daily with 20 µL of either 0.002% OMDI or vehicle. On day 7 of dosing, IOP was measured by pneumatonometry, aqueous humor flow and outflow facility were evaluated by fluorophotometry, and uveoscleral outflow was calculated mathematically. Treatments were compared by paired t-tests.

Results : OMDI at 0.002% significantly lowered IOP by 27%, 35%, and 44% at 0.5, 1.5, and 4 hours after the last dosing, respectively. There was no difference in aqueous humor flow between vehicle and OMDI treatments. When comparing OMDI to the vehicle treatment, outflow facility and uveoscleral outflow were significantly (P < 0.05) increased by 71% and 176%, respectively.

Conclusions : OMDI, a novel IOP-lowering compound, reduced IOP by increasing outflow facility and uveoscleral outflow in nonhuman primates.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×